Overview

Topical Timolol Gel for the Treatment of Infantile Hemangiomas

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
We plan to conduct a study, to see how safe and effective timolol maleate 0.5% gel-forming solution is for infantile hemangiomas (IH) and the response of hemangiomas to timolol maleate 0.5% . Our hypothesis is that timolol will inhibit and possibly reverse growth of appropriate infantile hemangiomas.
Phase:
Phase 2
Details
Lead Sponsor:
Rady Children's Hospital, San Diego
Collaborators:
ICN Pharmaceuticals
Valeant Pharmaceuticals
Treatments:
Maleic acid
Timolol